Working… Menu
Trial record 1 of 2 for:    grapiprant
Previous Study | Return to List | Next Study

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03696212
Recruitment Status : Terminated (Based on the totality of the generated combined safety and efficacy data in the interim period, the company decided to terminate the combination study in NSCLC patients. There are no subjects on study drug at this time or in the EOT Follow-up period.)
First Posted : October 4, 2018
Last Update Posted : February 21, 2021
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Arrys Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : February 15, 2021
Actual Study Completion Date : February 15, 2021